CANDEL THERAPEUTICS, INC. Increase (Decrease) in Accrued Liabilities
CANDEL THERAPEUTICS, INC. (CADL) reported Increase (Decrease) in Accrued Liabilities of -$346.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $3.51M, a 212.18% increase year-over-year.
- CANDEL THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$3.86M.
- CANDEL THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $2.29M, a 320.77% increase year-over-year.
- CANDEL THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $1.21M, a 10.78% decline year-over-year.
- CANDEL THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2025 was $2.25M, a 197.75% increase from fiscal 2024.
- CANDEL THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2024 was $757.00K.
- CANDEL THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2023 was -$301.00K, a 123.79% decline from fiscal 2022.
- CANDEL THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2022 was $1.26M, a 325.93% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$346.00K 10-Q · filed 2026-08-13 | $1.94M derived: sum of 3 quarters · filed 2026-08-13 | $3.15M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$3.86M 10-Q · filed 2026-05-14 | -$1.57M derived: sum of 2 quarters · filed 2026-05-14 | -$361.00K derived: sum of 3 quarters · filed 2026-05-14 | $764.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.50M derived: sum of 2 quarters · filed 2026-03-12 | $4.62M derived: sum of 3 quarters · filed 2026-08-13 | $2.25M 10-K · filed 2026-03-12 |
| 2025-09-30 | $1.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.33M derived: sum of 2 quarters · filed 2026-08-13 | -$35.00K 10-Q · filed 2025-11-13 | $509.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.24M 10-Q · filed 2026-08-13 | -$699.00K derived: sum of 3 quarters · filed 2026-08-13 | $655.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$2.37M 10-Q · filed 2026-05-14 | -$1.82M derived: sum of 2 quarters · filed 2026-05-14 | -$470.00K derived: sum of 3 quarters · filed 2026-05-14 | -$27.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $544.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.90M derived: sum of 2 quarters · filed 2026-03-12 | $2.34M derived: sum of 3 quarters · filed 2026-03-12 | $757.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.80M derived: sum of 2 quarters · filed 2025-11-13 | $213.00K 10-Q · filed 2025-11-13 | $1.16M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $443.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$1.14M 10-Q · filed 2025-08-14 | -$195.00K derived: sum of 3 quarters · filed 2025-08-14 | -$280.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$1.58M 10-Q · filed 2025-05-13 | -$638.00K derived: sum of 2 quarters · filed 2025-05-13 | -$723.00K derived: sum of 3 quarters · filed 2025-05-13 | -$95.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $946.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $861.00K derived: sum of 2 quarters · filed 2025-03-13 | $1.49M derived: sum of 3 quarters · filed 2025-03-13 | -$301.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | -$85.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $543.00K derived: sum of 2 quarters · filed 2024-11-14 | -$1.25M 10-Q · filed 2024-11-14 | -$812.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $628.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$1.16M 10-Q · filed 2024-08-13 | -$727.00K derived: sum of 3 quarters · filed 2024-08-13 | -$173.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$1.79M 10-Q · filed 2024-05-14 | -$1.35M derived: sum of 2 quarters · filed 2024-05-14 | -$801.00K derived: sum of 3 quarters · filed 2024-05-14 | -$615.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $435.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $989.00K derived: sum of 2 quarters · filed 2024-03-28 | $1.18M derived: sum of 3 quarters · filed 2024-03-28 | $1.26M 10-K · filed 2024-03-28 |
| 2022-09-30 | $554.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $740.00K derived: sum of 2 quarters · filed 2023-11-09 | $830.00K 10-Q · filed 2023-11-09 | $1.55M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $186.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $276.00K 10-Q · filed 2023-08-10 | $995.00K derived: sum of 3 quarters · filed 2023-08-10 | $1.80M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $90.00K 10-Q · filed 2023-05-11 | $809.00K derived: sum of 2 quarters · filed 2023-05-11 | $1.61M derived: sum of 3 quarters · filed 2023-05-11 | $1.66M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $719.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $1.52M derived: sum of 2 quarters · filed 2023-03-30 | $1.57M derived: sum of 3 quarters · filed 2023-03-30 | $297.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | $806.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $853.00K derived: sum of 2 quarters · filed 2022-11-10 | -$422.00K 10-Q · filed 2022-11-10 | $967.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $47.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | -$1.23M 10-Q · filed 2022-08-05 | $161.00K derived: sum of 3 quarters · filed 2022-08-05 | $293.00K derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | -$1.27M 10-Q · filed 2022-05-12 | $114.00K derived: sum of 2 quarters · filed 2022-05-12 | $246.00K derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $1.52M derived: sum of 2 quarters · filed 2022-03-29 | $1.51M 10-K · filed 2022-03-29 | |
| 2020-09-30 | $132.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $123.00K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | -$9.00K 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |